相关临床试验
746
168 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
18
2.4%
已完成
206
27.6%
Enrolling By Invitation
17
2.3%
尚未招募
133
17.8%
招募中
162
21.7%
终止
2
0.3%
Unknown
207
27.8%
撤回
1
0.1%
暂无批准数据
- IBI3016, an experimental siRNA therapy targeting angiotensinogen mRNA, achieved over 95% maximum reduction in AGT levels with sustained inhibition lasting up to six months after a single subcutaneous dose. - Phase 1 trial data presented at AHA 2025 showed significant blood pressure reductions across all treatment cohorts at three months, with the highest dose group demonstrating -16.7/-14.7 mmHg daytime BP changes compared to -3.2/-5.7 mmHg for placebo. - The therapy demonstrated favorable safety and tolerability over six months with no severe adverse events, serious adverse events, or hypotension events observed in the 40-patient study. - Results support the potential for biannual subcutaneous dosing to address medication adherence challenges in hypertension treatment, with next-phase development scheduled to initiate soon.
- MTS-004 has become China's first AI-enabled formulation drug candidate to successfully complete Phase III clinical trials, marking a significant milestone in AI-driven pharmaceutical development. - The drug targets Pseudobulbar Affect (PBA), a neurological condition causing involuntary laughing and crying episodes, representing the first and only therapy for this indication to reach Phase III in China. - Using METiS TechBio's proprietary AiTEM platform, the drug development timeline was compressed from the typical industry average to just 38 months from concept to Phase III completion. - The Phase III trial demonstrated statistically significant improvements in PBA symptoms, with therapeutic benefits observable as early as week 2 and sustained improvement throughout the 12-week treatment period.
